Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Anokion SA

Anokion Announces the Early Completion of Enrollment in the ACeD-it Phase 2 and the SynCeD Phase 2a Trials of KAN-101 for the Treatment of Celiac Disease
From Anokion SA
Via Business Wire
Anokion Announces New Data from the Phase 1 MoveS-it Study Supporting ANK-700 as a Novel, Potential Disease Modifying Treatment for Relapsing-Remitting Multiple Sclerosis
From Anokion SA
Via Business Wire
Anokion Announces New Clinical Data from the Phase 1b/2 ACeD-it Trial Supporting KAN-101 as a Potential Disease-Modifying Treatment for Celiac Disease
From Anokion SA
Via Business Wire
Anokion to Participate in BofA Healthcare Trailblazers Conference
From Anokion SA
Via Business Wire
Anokion Announces Clinical Progress with KAN-101 and ANK-700
From Anokion SA
Via Business Wire
Anokion Strengthens its Senior Leadership with Promotions and New Appointment
From Anokion SA
Via Business Wire
Anokion Announces Publication in The Lancet Gastroenterology & Hepatology Highlighting Safety and Preliminary Effects of KAN-101 in Celiac Disease in its ACeD Phase 1 Clinical Trial
From Anokion SA
Via Business Wire
Anokion Announces New Clinical Data from the Phase 1 ACeD Trial Supporting KAN-101 as a Potential Disease-modifying Treatment for Celiac Disease
From Anokion SA
Via Business Wire
Anokion Announces Leadership Team Expansion to Support Advancement of Clinical-Stage Autoimmune Pipeline
From Anokion SA
Via Business Wire
Anokion Announces Presentation of Data from Phase 1 ACeD Clinical Trial Evaluating KAN-101 as a Treatment for Celiac Disease at the 19th International Celiac Disease Symposium
From Anokion SA
Via Business Wire
Anokion Announces $35 Million Equity Investment from Pfizer
From Anokion SA
Via Business Wire
Anokion Announces Positive Data from Phase 1 ACeD Clinical Trial Evaluating KAN-101 as a Treatment for Celiac Disease Presented in a Plenary Session at DDW 2022
From Anokion SA
Via Business Wire
Anokion Announces Progress Across Pipeline of Novel Autoimmune Programs
From Anokion SA
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.